Pfizer Inc. (PFE)

NYSE: PFE · IEX Real-Time Price · USD
+0.03 (0.11%)
At close: Mar 1, 2024, 4:00 PM
-0.01 (-0.04%)
After-hours: Mar 1, 2024, 7:59 PM EST
Market Cap 150.15B
Revenue (ttm) 58.50B
Net Income (ttm) 2.12B
Shares Out 5.65B
EPS (ttm) 0.37
PE Ratio 71.86
Forward PE 11.96
Dividend $1.68 (6.32%)
Ex-Dividend Date Jan 25, 2024
Volume 39,196,138
Open 26.83
Previous Close 26.56
Day's Range 26.51 - 26.90
52-Week Range 25.76 - 42.22
Beta 0.57
Analysts Buy
Price Target 36.88 (+38.7%)
Earnings Date Jan 30, 2024

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]

Sector Healthcare
Founded 1849
Employees 88,000
Stock Exchange NYSE
Ticker Symbol PFE
Full Company Profile

Financial Performance

In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $36.88, which is an increase of 38.70% from the latest price.

Price Target
(38.70% upside)
Analyst Consensus: Buy
Stock Forecasts


Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition

Pharma giant Pfizer, fresh off its $43 billion acquisition of Seagen, said it will shut down construction on a new 270,000 square-foot manufacturing facility Seagen was building north of Seattle near ...

1 day ago - GeekWire

Pfizer says its RSV shot is protective through a second year

Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second year of respiratory disease se...

3 days ago - Reuters

Pfizer RSV vaccine maintains protection in older adults over two seasons in trial

The results come ahead of a meeting of an advisory panel to the CDC, which will consider whether seniors should take RSV shots annually or every other year.

3 days ago - CNBC

Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older followin...

3 days ago - Business Wire

Best Stocks to Buy Now

Our list of the best stocks to buy now reflect the lesson of the past few years: Be ready for anything.

4 days ago - Kiplinger

Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?

Pfizer PFE (NYSE: PFE) reported its Q4 results last month, with revenues missing but earnings beating the street estimates. The company reported revenue of $14.2 billion and an adjusted profit of $0.1...

5 days ago - Forbes

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President,...

6 days ago - Business Wire

Pfizer Stock Has 29% Upside, Says a New Bull

Guggenheim analysts initiated coverage of drug firm Pfizer at Buy with a $36 price target. Shares have lagged behind the market in recent years.

9 days ago - Barrons

Pfizer's expectations have been rightsized, has potential for $5 EPS: Cantor Fitzgerald's Chen

Louise Chen, Cantor Fitzgerald, and Michael Yee, Jefferies, joins 'Power Lunch' to discuss Chen's bull case for Pfizer, Yee's bull case for Moderna, and more.

10 days ago - CNBC Television

Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

--VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU-- SHANGHAI , Feb. 21, 2024 /PRNewswire/ -- Everest Medicines ...

11 days ago - PRNewsWire

Pfizer inflammatory bowel disease drug wins European Commission approval

Pfizer on Monday said the European Commission has approved the company's drug to treat patients with an inflammatory bowel disease called ulcerative colitis.

13 days ago - Reuters

European Commission Approves Pfizer's VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patie...

13 days ago - Business Wire

Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Oncology Innovation Day on Thursday, February 29, 2024, from 1:00 p.m....

17 days ago - Business Wire

Pfizer at 10-year support: Is it a massive buy opportunity?

For shareholders of the multinational biotech giant Pfizer Inc. NYSE: PFE, it might feel like the stock's all-time highs set during the pandemic were centuries ago. After making its COVID-19-related a...

17 days ago - MarketBeat

Pfizer agrees to pay $93 mln to settle Lipitor antitrust lawsuit

Pfizer has agreed to pay $93 million to settle antitrust claims by wholesale drug distributors that accused it of conspiring with India's Ranbaxy Laboratories to delay sales of less expensive, generic...

18 days ago - Reuters

Pfizer CEO doubles down on 2024 guidance, talks Seagen buy

Pfizer (PFE) reported fourth-quarter earnings on Tuesday morning that beat. Wall Street expectations.

4 weeks ago - Yahoo Finance

How Pfizer (PFE) Can Succeed In A Post-Pandemic World

Pfizer's (PFE) 4Q adjusted EPS came in at $0.10 versus an estimated -$0.19 and revenue came in at $14.25B versus an estimated $14.36B. Lee Bohl and Sel Hardy discuss the takeaways from Pfizer's earnin...

4 weeks ago - Schwab Network

Pfizer posts unexpected Q4 earnings beat

Pfizer (PFE) shares are on the move after posting a mixed fourth-quarter earnings report, with adjusted earnings topping expectations, but missing revenue estimates. The pharmaceutical giant saw a sma...

4 weeks ago - Yahoo Finance

Pfizer Q4 Earnings Eke Out Unexpected Profit Despite Lower COVID Product Sales

Pfizer Inc. (PFE) delivered a surprise profit in the fourth quarter despite a double-digit contraction in revenue. Pfizer shares were up 1.8% in early trading Tuesday following the release.

4 weeks ago - Investopedia

BofA's Geoff Meacham on Pfizer earnings: The story is still about Covid contraction

Geoff Meacham, Bank of America Securities senior pharmaceuticals analyst, joins 'Squawk Box' to break down Pfizer's quarterly earnings results, Big Pharma 2024 outlook, and more.

4 weeks ago - CNBC Television

Pfizer beats earnings estimates as declining Covid business performs better than expected

CNBC's Mike Santoli reports on the company's quarterly earnings results.

4 weeks ago - CNBC Television

Pfizer's stock rises as earnings beat expectations, company seeks ‘clean slate' in 2024

Shares of Pfizer Inc. PFE, +0.04% gained 0.7% early Tuesday after the company beat analysts' earnings expectations and reaffirmed its full-year 2024 guidance issued in December.

4 weeks ago - Market Watch